{{Rsnum
|rsid=16953
|Chromosome=15
|Orientation=minus
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|position=25449892
|Status=Merged
|Merged=780
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 6.3 | 34.2 | 59.5
| HCB | 14.0 | 47.1 | 39.0
| JPT | 11.6 | 50.0 | 38.4
| YRI | 44.5 | 43.8 | 11.6
| ASW | 36.8 | 42.1 | 21.1
| CHB | 14.0 | 47.1 | 39.0
| CHD | 21.3 | 44.4 | 34.3
| GIH | 9.9 | 45.5 | 44.6
| LWK | 53.6 | 38.2 | 8.2
| MEX | 5.2 | 29.3 | 65.5
| MKK | 41.0 | 50.6 | 8.3
| TSI | 5.9 | 26.5 | 67.6
| HapMapRevision=28
}}{{PMID Auto
|PMID=23962907
|Title=ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy
}}